On August 31, 2022 Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, reported that Janux management will participate and present at two upcoming investor conferences (Press release, Janux Therapeutics, AUG 31, 2022, View Source [SID1234618840]). Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 17th Annual BioPharma Conference
Forum: 1×1 In-Person Investor Meetings
Date: Wednesday, September 7, 2022
Location: Boston, Massachusetts

H.C. Wainwright 24th Annual Global Investment Conference
Forum: Virtual Fireside Chat and Virtual Investor Meetings
Dates: Monday, September 12 to Thursday, September 15, 2022

The fireside chat will be available for on-demand viewing beginning September 12 at 7:00 a.m. ET via the Investors & Media section of Janux’s website. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.